MedTrace Logo

Mitochondrial dysfUnction: a Key Player in Doxorubicin-induced Skeletal and Cardiac muscLE Damage

NCT05731375 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2026-05-11

No results posted yet for this study

Summary

The goal of this observational study is to demonstrate the ability of using non-invasive Phosphorus (31P) Magnetic Resonance Spectroscopy (MRS) to monitor changes of in-vivo markers of mitochondrial function in skeletal and cardiac muscles in muscles in patients with cancer treated with anthracyclines and/or platinum-derivates. The main question it aims to answer is:

• Can 31P-MRS be used to monitor changes of in vivo markers of mitochondrial function in skeletal and cardiac muscles in patients with cancer undergoing treatment with anthracyclines and or platinum derivates?

To be able to answer this main question, participants will undergo 31P-MRS imaging of the calf muscles and of the heart 3 times during the study period.

Conditions

  • Doxorubicin Induced Cardiomyopathy
  • Chemotherapeutic Toxicity
  • Anthracyclines

Interventions

DIAGNOSTIC_TEST

31-MRS at 7 Tesla (T)

31-MRS imaging at 7T to evaluate mitochondrial function in skeletal and cardiac muscles.

Sponsors & Collaborators

  • Julius Clinical

    collaborator INDUSTRY

  • UMC Utrecht

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-28
Primary Completion
2026-03-20
Completion
2026-03-20

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05731375 on ClinicalTrials.gov